JP5863058B2 - １Ｈ−イミダゾ［４，５−ｃ］キノリン - Google Patents
１Ｈ−イミダゾ［４，５−ｃ］キノリン Download PDFInfo
- Publication number
- JP5863058B2 JP5863058B2 JP2013510600A JP2013510600A JP5863058B2 JP 5863058 B2 JP5863058 B2 JP 5863058B2 JP 2013510600 A JP2013510600 A JP 2013510600A JP 2013510600 A JP2013510600 A JP 2013510600A JP 5863058 B2 JP5863058 B2 JP 5863058B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- hydrogen
- mmol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C=C(C1=C2)N=Cc3c1[n](*)c(*)n3)C=C2IN(*)C(C(CCCCC(C)(*)CN1C(*)(*)C2=CC=CC=CC=CC=C2)C1=O)=O Chemical compound CC(C)(C=C(C1=C2)N=Cc3c1[n](*)c(*)n3)C=C2IN(*)C(C(CCCCC(C)(*)CN1C(*)(*)C2=CC=CC=CC=CC=C2)C1=O)=O 0.000 description 9
- OTEYMFHJOGZWEY-UHFFFAOYSA-N CB1N(C(C)C)[O]=CC1 Chemical compound CB1N(C(C)C)[O]=CC1 OTEYMFHJOGZWEY-UHFFFAOYSA-N 0.000 description 1
- BJASKFJOOPKHCP-UHFFFAOYSA-N CC(C)C1=CC=CN(C(C)C)C1=O Chemical compound CC(C)C1=CC=CN(C(C)C)C1=O BJASKFJOOPKHCP-UHFFFAOYSA-N 0.000 description 1
- URJWPXSKERUJDM-UHFFFAOYSA-N CC(C)C1=CC=NN(C(C)C)C1O Chemical compound CC(C)C1=CC=NN(C(C)C)C1O URJWPXSKERUJDM-UHFFFAOYSA-N 0.000 description 1
- SBVKGVYNOGLCQM-UHFFFAOYSA-N CC(C)C1=CN=CN(C(C)C)C1=O Chemical compound CC(C)C1=CN=CN(C(C)C)C1=O SBVKGVYNOGLCQM-UHFFFAOYSA-N 0.000 description 1
- VTCNAFJVMVOREN-UHFFFAOYSA-N CC(C)C1=CNN(C(C)C)C1=O Chemical compound CC(C)C1=CNN(C(C)C)C1=O VTCNAFJVMVOREN-UHFFFAOYSA-N 0.000 description 1
- WESZMPDHRHUYCP-UHFFFAOYSA-N CC(C)C1=NC=CN(C(C)C)C1=O Chemical compound CC(C)C1=NC=CN(C(C)C)C1=O WESZMPDHRHUYCP-UHFFFAOYSA-N 0.000 description 1
- BHJVEEXWNLSRAO-UHFFFAOYSA-N C[n]1c2c(cc(cc3)C#CCNC(C4=CN=CN(Cc(cc5)cc(F)c5F)C4=O)=O)c3ncc2nc1CCOC Chemical compound C[n]1c2c(cc(cc3)C#CCNC(C4=CN=CN(Cc(cc5)cc(F)c5F)C4=O)=O)c3ncc2nc1CCOC BHJVEEXWNLSRAO-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10163019 | 2010-05-17 | ||
| EP10163019.2 | 2010-05-17 | ||
| PCT/EP2011/057985 WO2011144622A1 (en) | 2010-05-17 | 2011-05-17 | 1h - imidazo [4, 5 - c] quinolines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013526559A JP2013526559A (ja) | 2013-06-24 |
| JP2013526559A5 JP2013526559A5 (https=) | 2014-07-10 |
| JP5863058B2 true JP5863058B2 (ja) | 2016-02-16 |
Family
ID=42989490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510600A Active JP5863058B2 (ja) | 2010-05-17 | 2011-05-17 | １Ｈ−イミダゾ［４，５−ｃ］キノリン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8895581B2 (https=) |
| EP (1) | EP2571877B1 (https=) |
| JP (1) | JP5863058B2 (https=) |
| WO (1) | WO2011144622A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011144622A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | 1h - imidazo [4, 5 - c] quinolines |
| WO2014001973A1 (en) | 2012-06-29 | 2014-01-03 | Pfizer Inc. | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| IL311202A (en) * | 2013-11-15 | 2024-05-01 | Oncoceutics Inc | 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| WO2016123571A1 (en) | 2015-01-30 | 2016-08-04 | Oncoceutics Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
| KR102161364B1 (ko) * | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| WO2018163066A1 (en) * | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| JP7433291B2 (ja) * | 2018-08-16 | 2024-02-19 | イネイト・テューマー・イミュニティ・インコーポレイテッド | イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| US12600717B2 (en) | 2021-07-14 | 2026-04-14 | Incyte Corporation | Tricyclic compounds as inhibitors of KRAS |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| DE602004014969D1 (de) | 2003-11-21 | 2008-08-21 | Novartis Ag | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
| AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CA2634017A1 (en) | 2005-12-16 | 2007-07-05 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods |
| US8778977B2 (en) * | 2006-06-30 | 2014-07-15 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl PDK1 inhibitors |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| US8575203B2 (en) * | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| WO2011144622A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | 1h - imidazo [4, 5 - c] quinolines |
-
2011
- 2011-05-17 WO PCT/EP2011/057985 patent/WO2011144622A1/en not_active Ceased
- 2011-05-17 JP JP2013510600A patent/JP5863058B2/ja active Active
- 2011-05-17 US US13/697,034 patent/US8895581B2/en active Active
- 2011-05-17 EP EP11720100.4A patent/EP2571877B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8895581B2 (en) | 2014-11-25 |
| WO2011144622A1 (en) | 2011-11-24 |
| EP2571877B1 (en) | 2018-08-15 |
| EP2571877A1 (en) | 2013-03-27 |
| JP2013526559A (ja) | 2013-06-24 |
| US20130210832A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5863058B2 (ja) | １Ｈ−イミダゾ［４，５−ｃ］キノリン | |
| JP5871896B2 (ja) | Ｂ−ｒａｆキナーゼインヒビター | |
| JP5959754B2 (ja) | トリアゾロピラジン | |
| JP6370368B2 (ja) | Ｂｒｄ４阻害剤としてのインドリノン類似体 | |
| JP6495908B2 (ja) | ピリジノン | |
| JP5991974B2 (ja) | 新規アミノピラゾロキナゾリン | |
| JP5850952B2 (ja) | セリン／スレオニンキナーゼ阻害剤としての新しいアザインドリルフェニルスルホンアミド | |
| JP6128133B2 (ja) | Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン | |
| JP6085873B2 (ja) | トリアゾロピリダジン | |
| JP6370376B2 (ja) | Ｂｒｄ４阻害薬としてのトリアゾロピラジン誘導体 | |
| JP5871897B2 (ja) | ピリジルトリアゾール | |
| JP6488367B2 (ja) | ベンゾイミダゾール誘導体 | |
| JP5860031B2 (ja) | Ｐｄｋ１阻害薬としてのヘテロ環式カルボン酸アミド | |
| JP5824068B2 (ja) | セリン／トレオニンキナーゼ阻害剤としての新規トリアゾリルフェニルスルホンアミド | |
| JP6424224B2 (ja) | 新規ビスアミドピリジン | |
| JP2017527532A (ja) | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 | |
| JP2016515561A (ja) | Ｂｒｄ４阻害薬としてのジヒドロキナゾリノン類似体 | |
| JP2014503570A (ja) | 新規な５−アルキニル−ピリジン | |
| JP2014503571A (ja) | 新規な５−アルキニル−ピリジン | |
| HK1180313A (en) | New aminopyrazoloquinazolines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140519 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140519 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150630 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151202 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151217 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5863058 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |